Bio Pharma Dive
DECEMBER 23, 2020
The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.
World of DTC Marketing
DECEMBER 23, 2020
According to a study in the Journal for American Board of Family Medicine “respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. Among the 26% of respondents who talked to a health care provider about a specific prescription drug they saw advertised, 16% said they received a prescription for the advertised drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
DECEMBER 22, 2020
Murepavadin is being developed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis
NY Times
DECEMBER 25, 2020
The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
DECEMBER 22, 2020
In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb.
World of DTC Marketing
DECEMBER 22, 2020
Consumers downloaded 204 billion apps in 2019, and mobile use has been increasing during the pandemic. Apple, with its new privacy requirements, is challenging app developers and brands while Facebook cries fowl. It will have little effect on app use, though, for consumers. In 2020, there should be over 592 million daily app downloads, and a survey by Gallup revealed that nearly half (45%) of Americans have at least tried digital health products such as fitness trackers or mobile health apps.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
DECEMBER 23, 2020
BioSpace spoke with just a couple of companies endeavoring to make 2021 a happier new year for survivors now suffering from the life-altering after-effects of COVID-19.
Bio Pharma Dive
DECEMBER 21, 2020
Servier will pay Agios $1.8 billion upfront to acquire the biotech's approved leukemia treatment Tibsovo as well as the rest of its pipeline in cancer and early-stage research work.
World of DTC Marketing
DECEMBER 21, 2020
It’s hard to believe that 2020 is almost over but goodbye and good riddance. I’m hoping a new leader can restore the CDC and FDA’s trust and that the nationwide vaccination problem can proceed, but there are bigger issues. Long after COVID is a bad memory, the pharma industry will still be making more and more mistakes in the name of profits.
Pharma Times
DECEMBER 21, 2020
EGFR-TKI approved in the US for early non-small cell lung cancer
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Outsourcing Pharma
DECEMBER 23, 2020
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
Bio Pharma Dive
DECEMBER 23, 2020
The new deal will provide the U.S. with 100 million additional doses of Pfizer and BioNTech's shot, but the much-needed supply won't be available for several months.
World of DTC Marketing
DECEMBER 24, 2020
This year I passed 750,000 readers and I could not be more thrilled. I know you love the industry as much as I do and that there is much work still to be done. May you holiday season be filled with great memories. The post The best to all appeared first on World of DTC Marketing.com.
Scienmag
DECEMBER 20, 2020
Credit: CEM Ivory Coast has announced the creation of its first Marine Protected Area (MPA). The MPA will cover 2,600km2 (1,000 square miles) of pristine ocean off the coast of Grand-Béréby, protecting marine biodiversity including threatened shark and turtle species. The announcement is the culmination of years of work by the Ivorian government, the Abidjan […].
Pharma Times
DECEMBER 21, 2020
Drug becomes first treatment for peanut allergy in the EU
Bio Pharma Dive
DECEMBER 21, 2020
The FDA halted the AMT-061 program, which could be the first approved gene therapy for hemophilia B, because a patient who received the treatment appears to have developed liver cancer.
BioPharma Reporter
DECEMBER 22, 2020
BioNTech's CEO says it is highly likely that the Pfizer/BioNTech vaccine will be able to deal with the new variant that has emerged in the UK. And a new vaccine could be developed within six weeks if needed.
Pharma Mirror
DECEMBER 23, 2020
Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
DECEMBER 23, 2020
REACH-CDM study was based on results of positive phase II data
Bio Pharma Dive
DECEMBER 21, 2020
Twelve-week dosing for faricimab would help Roche's competitive position, but copycat drugs for existing treatments could soon flood the market.
BioSpace
DECEMBER 21, 2020
At the moment, eight clinical trials are currently being carried out to determine if the link between melatonin and the novel coronavirus is legitimate.
Pharma Mirror
DECEMBER 23, 2020
During the last couple of years, medical software has gained a lot of momentum. It’s crucial for monitoring the health of patients, and it’s one of the best ways to put human ingenuity to use. The market for this niche is getting bigger, and it’s going to cross 30 billion dollars soon. Managers and local clinics need to know about all the benefits of using these kinds of programs.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
DECEMBER 23, 2020
Submission supported by results from phase II CodeBreaK 100 study
Bio Pharma Dive
DECEMBER 22, 2020
Following a string of deals in edgy, unproven fields of scientific research, Vertex's latest diversification push involves chemical-based drugs that target RNA — an approach that's already attracted several large pharmas.
pharmaphorum
DECEMBER 24, 2020
The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. If the vaccine becomes available the UK will be able to step up its vaccination programme as large swathes of the country face draconian “Tier 4” restrictions due to the emergence of as more infectious variant.
Pharmacy Checkers
DECEMBER 23, 2020
With some stops and starts, this blog has become far more focused on policy, regulatory matters, law and politics — and less on everyday consumer issues relating to drug prices. With Christmas upon us, I want to extoll PharmacyChecker.com’s simple core mission: make it easier for Americans to pay for their prescription drugs. Ask PharmacyChecker , the consumer journalistic section of PharmacyChecker, has a great piece up today called The Gift of Low Drug Prices.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
DECEMBER 23, 2020
Payment for drug linked to value to NHS rather than volume used
Bio Pharma Dive
DECEMBER 21, 2020
The regulator declined to approve inclisiran, which Novartis acquired in its buyout of The Medicines Co., after agency staff weren't able to inspect a production facility in Europe.
pharmaphorum
DECEMBER 21, 2020
2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most deals focused on specific drugs from biotechs, particularly in cancer (though we did get rumours of an AstraZeneca-Gilead merger , which would have been the
BioSpace
DECEMBER 22, 2020
It is already a very Merry Christmas for brand new San Diego-based biotech Neomorph, Inc., which found $109 million under the tree in a Series A financing to advance its proprietary protein degradation platform and programs.
Expert insights. Personalized for you.
364 
Let's personalize your content